| A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity (NCT07747857) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-09-01 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® (NCT07663526) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-08-01 |
| Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects (NCT07697443) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-08-01 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT07753369) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-08-01 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants (NCT07708272) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07-30 |
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets (NCT07608666) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07-20 |
| A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis (NCT07663331) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07-14 |
| Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors (NCT07738679) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07-01 |
| A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease (NCT07633314) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07-01 |
| Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria (NCT07512596) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-07-01 |
| A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus (NCT07509892) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-06-22 |
| A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis (NCT07551427) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-06-18 |
| Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma (NCT07569757) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-06-01 |
| Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease (NCT07564505) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-05-01 |
| A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis (NCT07529925) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-05-01 |
| Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors (NCT07482592) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-04-15 |
| Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma (NCT07548177) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-04-02 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects (NCT07480824) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-04-01 |
| A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function (NCT07538973) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-04-01 |
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas (NCT07407803) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-03-31 |
| A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis (NCT07314060) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-03-19 |
| Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (NCT07464587) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-03-01 |
| A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection (NCT07367529) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-02-26 |
| To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors (NCT07338838) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-02-26 |
| Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer (NCT07367516) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-02-12 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors (NCT07269145) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-01-22 |
| A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (NCT07252908) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-12-22 |
| A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects (NCT07327281) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-12-18 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors (NCT07291050) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-12-01 |
| Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets (NCT07172126) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-09-01 |
| Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (NCT07147946) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-09-01 |
| A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults (NCT07083739) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-08-01 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects (NCT06990776) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-07-09 |
| A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors (NCT06943677) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-05-26 |
| Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (NCT06851442) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-05-16 |
| A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia (NCT06900920) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-30 |
| Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (NCT06829771) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-23 |
| A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma (NCT06860971) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-18 |
| Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C (NCT06821503) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-11 |
| Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (NCT06897579) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-04-07 |
| Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) (NCT06859931) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-03-01 |
| A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects (NCT06738979) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-03-01 |
| Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer (NCT06702618) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-02-20 |
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease (NCT06711991) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-02-11 |
| Clinical Trial of TQB3002 in Patients With Advanced Cancers (NCT06662760) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-12-09 |
| Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection (NCT06706310) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-12-04 |
| A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease (NCT06748079) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-12-03 |
| Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease (NCT06682169) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-11-20 |
| To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency (NCT06672276) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-11-20 |
| Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection (NCT06644417) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-11-14 |
| A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma (NCT06566586) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-11-06 |
| Drug-Drug Interaction (DDI) Study for TQB3616 (NCT06662773) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-11-01 |
| To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects (NCT06598956) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-10-12 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06527144) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-09-14 |
| A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients (NCT06469879) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-09-01 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer (NCT06561607) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-08-01 |
| To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects (NCT06522945) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-07-24 |
| Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock (NCT06351150) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-07-23 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects (NCT06448273) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-07-19 |
| Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps (NCT06439381) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-07-16 |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer (NCT06475599) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-07-01 |
| TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors (NCT06500091) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-07-01 |
| A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors (NCT06413953) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-06-27 |
| A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions (NCT06487416) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-06-10 |
| A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B (NCT06452693) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-06-01 |
| A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer (NCT06415903) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-06-01 |
| Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. (NCT06320080) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-30 |
| TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. (NCT06297642) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-24 |
| A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects (NCT06408285) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-22 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (NCT06245941) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-13 |
| A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease (NCT06300320) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-07 |
| The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma (NCT06434467) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-05-01 |
| A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer (NCT06344351) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-04-25 |
| A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies (NCT07011186) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-04-17 |
| D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure (NCT06300177) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-03-28 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B (NCT06566248) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-03-20 |
| A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects (NCT07293390) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-03-18 |
| A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot) (NCT06326671) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-02-28 |
| A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (NCT06198751) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-02-05 |
| A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. (NCT06010901) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-01-13 |
| Mass Balance Study of TQB3616 (NCT06149611) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-01-01 |
| A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy (NCT06211751) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-01-01 |
| A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (NCT06160895) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-26 |
| A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) (NCT06122831) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-12 |
| A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps (NCT06036927) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-08 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B (NCT06150014) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-07 |
| A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets (NCT06165822) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-01 |
| A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer (NCT06165809) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-12-01 |
| A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects (NCT06085053) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-11-30 |
| A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects (NCT06139367) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-11-01 |
| A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects (NCT06126562) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-10-31 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (NCT05959694) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-10-11 |
| A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (NCT06024915) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-09-21 |
| A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma. (NCT05987358) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-09-21 |
| Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy (NCT06008405) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-09-01 |
| A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis (NCT05849727) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-30 |
| A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. (NCT05987371) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-23 |
| A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor (NCT05997342) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-16 |
| A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). (NCT05975645) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-15 |
| Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma (NCT05994365) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2023-08-01 |